Please select the option that best describes you:
Are there any data for second line nivolumab-ipilimumab in patients with metastatic NSCLC treated with either single agent pembrolizumab or chemotherapy + ICI as first line therapy?
Would you consider second line nivo-ipi for patients with a specific histology or tumor PD-L1 expression?
Answer from: Medical Oncologist at Academic Institution
Resistance to PD-(L)1 inhibitor based first line therapy and choice of subsequent treatment for patients with advanced NSCLC is an ongoing challenge. While addition of CTLA-4 inhibitor to PD-1 inhibitor has shown additive anti-tumor activity via complementary mechanisms of action, it is currently un...
Sign in or Register to read more